Sera Prognostics (SERA) EBITDA Margin (2020 - 2026)
Sera Prognostics (SERA) posted EBITDA Margin of 66857.14% for Q1 2026, up 25.33% on a QoQ basis from 89540.0% in Q4 2025, and down 4251504.0% year-over-year from N/an in Q1 2025.
Sera Prognostics (SERA) EBITDA Margin (2020 - 2026) Analysis & Trends
Sera Prognostics' EBITDA Margin history runs 7 years deep, the most recent figure standing at 66857.14% for Q1 2026.
- Quarterly EBITDA Margin fell 4251504.0% year-over-year to 66857.14% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 64235.09% (down 3224552.0% YoY) and the FY2025 annual result came in at 45066.67%, up 251126.0% from the prior year.
- EBITDA Margin was 66857.14% for Q1 2026 at Sera Prognostics, up from 89540.0% in the prior quarter.
- Across five years, EBITDA Margin topped out at 9317.07% in Q2 2023 and bottomed at 89540.0% in Q4 2025.
- A 5-year average of 33630.64% and a median of 27450.36% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin surged 3223000 bps — and 2025, when it plunged 5027750 bps.
- Sera Prognostics' EBITDA Margin stood at 16027.69% in 2022, then slumped by 35 bps to 21580.49% in 2023, then sank by 82 bps to 39262.5% in 2024, then plunged by 128 bps to 89540.0% in 2025, then increased by 25 bps to 66857.14% in 2026.
- Business Quant data shows SERA's EBITDA Margin at 66857.14% in Q1 2026, 89540.0% in Q4 2025, and 56125.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Sera Prognostics | 109.06 Mn | 109.06 Mn | -28,000.00 | -66,857.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66,857.14% |
| Dec 31, 2025 | -89,540.00% |
| Sep 30, 2025 | -56,125.00% |
| Jun 30, 2025 | -54,823.53% |
| Mar 31, 2025 | -24,342.11% |
| Dec 31, 2024 | -39,262.50% |
| Sep 30, 2024 | -30,558.62% |
| Jun 30, 2024 | -38,554.17% |
| Dec 31, 2023 | -21,580.49% |
| Sep 30, 2023 | -19,485.71% |
| Jun 30, 2023 | -9,317.07% |
| Mar 31, 2023 | -11,329.00% |
| Dec 31, 2022 | -16,027.69% |
| Sep 30, 2022 | -12,859.77% |
| Jun 30, 2022 | -15,058.97% |
| Mar 31, 2022 | -32,368.42% |
| Dec 31, 2021 | -48,257.69% |
| Sep 30, 2021 | -41,052.17% |
| Jun 30, 2021 | -36,905.00% |
| Mar 31, 2021 | -46,346.15% |